Lens epithelium-derived growth factor p75 (LEDGF/p75) is a nuclear autoantigen in atopic disorders implicated in cellular protection against stress-induced apoptosis. We observed that LEDGF/p75 was cleaved during apoptosis into fragments of 65 and 58 kD generated by caspases-3 and -7 cleaving at three sites: DEVPD 30 ;G, DAQD 486 ;G and WEID 85 ;N. Sequence analysis revealed that the DEVPD 30 ;G and WEID 85 ;N sites lie within the highly conserved HATH (homologous to amino terminus of hepatoma-derived growth factor) region, also known as PWWP domain. Alignment of proteins containing this domain failed to reveal conservation of the DEVPD 30 ;G and WEID 85 ;N sites, suggesting that the HATH/ PWWP domain of LEDGF/p75 may be specifically targeted by caspases. Overexpression of LEDGF/p75 protected HepG2 cells from serum starvation-induced cell death, whereas expression of the 65 kD fragment failed to protect. The apoptotic cleavage of LEDGF/p75 may contribute to the pathogenesis of atopic disorders by abrogating its prosurvival function and enhancing its immunogenicity. Cell Death and Differentiation (2002) 9, 915 ± 925.
Introduction
The prevalence of atopic disorders, which include atopic dermatitis (AD), asthma, and allergic rhinitis, is rising in Western countries. 1 AD is a chronic, highly pruritic inflammatory skin disorder that affects approximately 10 to 15% of the population at some time during childhood and often progresses to asthma and allergic rhinitis in the adult. 1 While patients with AD often have elevated serum IgE levels and sensitization to environmental allergens, there is evidence that many patients with mild to moderate AD lack clinically relevant sensitivities to food or aeroallergens. 2 Dysregulation of the immune system, mediated by both extrinsic and intrinsic factors, is believed to play a key role in the pathogenesis of AD. 3 In AD, disease exacerbation is often accompanied by increased IgG/IgE antibodies to self-intracellular proteins, implicating autoimmunity as an important pathogenetic factor in this condition. 4 ± 10 A major target of autoantibodies in AD is the dense fine speckles protein of 70 kD (DFS70), distributed in the nucleoplasm during interphase and in condensed chromosomes during mitosis. 4, 5 DFS70 is identical to the transcription co-activator p75 11 and the lens epithelial-derived growth factor (LEDGF) 12 and is also recognized by autoantibodies in other atopic and inflammatory disorders, including asthma, 4 interstitial cystitis, 4 age-related cataract, 12 and Vogt-Koyanagi-Harada (VKH) disease. 13 This nuclear autoantigen, better known as LEDGF/p75, is considered a novel survival protein that promotes mammalian cell growth and confers resistance to cell death induced by a wide range of environmental stresses including heat shock, oxidative stress, and serum-starvation. 12,14 ± 22 While the origin of autoimmunity to intracellular proteins in atopic disorders is unknown, it is presumed that abnormal cell death triggered by environmental allergens or intrinsic factors in the target organs of atopy (skin, eyes, respiratory and gastrointestinal tracts) might facilitate the sustained exposure of potentially immunostimulatory forms of intracellular autoantigens to the immune system. 6, 23 Consistent with this notion is that dysregulated keratinocyte apoptosis contributes to the development of the epidermal lesions associated with AD. 24, 25 Along with Rosen and colleagues, we have shown systematically that many intracellular autoantigens targeted by autoantibodies in systemic autoimmunity undergo proteolytic cleavage during both apoptotic and non-apoptotic cell death. 26 ± 31 This and other modifications might alter the function of autoantigens, enhance their immunogenicity by exposing cryptic epitopes, and stimulate autoantibody responses if they occur under a pro-inflammatory context. 31 ± 34 In this study we provide evidence that caspase-mediated cleavage of LEDGF/p75 during apoptosis abrogates its prosurvival function. The apoptotic cleavage of LEDGF/p75 may contribute to the pathogenesis of certain atopic and chronic inflammatory disorders by altering its pro-survival function and enhancing its immunogenicity.
Results

Cleavage of LEDGF/p75 during apoptosis
During a recent search for novel autoantigens cleaved during cell death, we observed that LEDGF/p75 (called DFS70 in that study) belongs to a subset of intracellular proteins that are cleaved during apoptosis and undergo a second wave of proteolysis as apoptosis progresses into secondary necrosis. 28 Here we sought to explore the cleavage mechanism of LEDGF/p75 during apoptosis and its biological consequences. Immunoblotting analysis of whole lysates from apoptotic Jurkat, NHEK (normal human epithelium keratinocytes) and Hela cells showed that LEDGF/p75 was cleaved into fragments of approximately 65 and 58 kD ( Figure 1A ). The 65 kD fragment appeared shortly after the cleavage of poly (ADP-ribose) polymerase (PARP), an early event in apoptosis, whereas the 58 kD fragment appeared later ( Figure 1B ). LEDGF/p75 cleavage was caspase-dependent since it could be inhibited with the pan-caspase inhibitor benzylozycarbonyl-Val-Ala-Asp-fluoromethylketone (zVADfmk) ( Figure 1C) . LEDGF/p75 cleavage did not appear to interfere with its localization to condensed chromatin, 4 since the protein colocalized with condensed, fragmented chromatin in NHEK undergoing staurosporine-induced apoptosis ( Figure  2 ). Approximately half of the NHEK population displayed nuclear apoptotic morphology after 8 h of staurosporine treatment, which correlated with the extent of LEDGF/p75 cleavage at this particular time point ( Figure 1A ). While LEDGF/p75 was almost entirely cleaved into the 65 kD fragment after 12 h of staurosporine treatment, colocalization of the protein with chromatin in the apoptotic cells was still evident at that time point (data not shown).
LEDGF/p75 is cleaved by caspases-3 and -7 in vitro
We examined whether caspases-3 and -7, the main effector caspases in apoptosis, 35 ± 38 cleave LEDGF/p75 in vitro. In vitro translated LEDGF/p75, fused to T7 protein and 6x histidine tags, migrated with an apparent molecular weight of 77 kD on SDS ± PAGE ( Figure 3A , untreated). Incubation of translated LEDGF/p75 with active recombinant caspases-3 and -7 resulted in a major cleavage fragment of approximately 65 kD and a minor fragment of 58 kD ( Figure 3A ). Caspases-6, -8, and -9 did not cleave the protein ( Figure 3A and data not shown). Incubation of the in vitro-translated LEDGF/p75 with increasing doses of recombinant caspases-3 and -7 showed that the 65 kD fragment was the predominant cleavage product ( Figure 3B ). The kinetics of in vitro cleavage revealed that the 65 kD fragment appeared first and subsequently underwent cleavage into the 58 kD fragment ( Figure 3C ).
Caspases-3 and -7 cleave LEDGF/p75 at various sites
Cleavage of in vitro-translated LEDGF/p75 by caspases-3 and -7 into 65 and 58 kD fragments suggested that the cleavage sites recognized by these caspases must be near Pretreatment of Jurkat cells with zVAD-fmk before induction of apoptosis with STS inhibited the cleavages of LEDGF/p75 and PARP. Proteins were detected with high titer, highly specific human autoantibodies to LEDGF/p75 or PARP. Lines indicate bands corresponding to intact proteins. Arrows indicate bands corresponding to cleavage fragments generated during apoptosis. Approximate molecular weights of the protein bands are shown. Molecular weights were derived using the Bio-Rad Precision Protein Standards (Bio-Rad Laboratories). Blots are representative of at least three independent experiments Figure 2 Immunofluorescence pattern of a highly specific anti-LEDGF/p75 human serum in control and STS-treated NHEK. Cells growing in coverslips were treated with STS for 8 h and then fixed/permeabilized with methanol/ acetone prior to immunostaining. Antibodies to LEDGF/p75 gave a distinctive dense fine speckled staining in nuclei of control NHEK. Corresponding images of nuclei counterstained with 4',6-diamidino-2-phenylindole (DAPI) are shown. Note the colocalization of the LEDGF/p75 and DAPI staining patterns in apoptotic nuclei from staurosporine-treated cells, indicated by arrows the NH 2 -or COOH-terminal regions. To map these sites, we first searched the LEDGF/p75 amino acid sequence for the presence of the DXXD sequence, which is the consensus cleavage motif recognized by caspases-3 and -7. Four such motifs were found near the NH 2 -and COOH-terminal regions: DEVPD 30 ;G, DNLD 369 ;V, DAQD 486 ;G, and DSKD 502 ;N ( Figure 4A ). Another potential caspase cleavage motif, WEID 85 ;N was also identified. While this site does not fit the consensus DXXD motif, we considered it because cleavage after Asp 85 would theoretically generate a *60 kD fragment and effector caspases are known to cleave at nonconventional sites. 39, 40 The predicted molecular weights of the fragments resulting from cleavage at some of these sites are depicted in Figure 4A . To confirm the cleavage sites, we constructed mutant forms of LEDGF/p75 in which Asp residues at position P1 of the potential caspase cleavage sites were substituted by Ala ( Figure 4B ). We predicted that these substitutions would block caspase recognition of the sites and inhibit cleavage.
Incubation of in vitro-translated LEDGF/p75 mutants with caspase-3 revealed that the mutants containing DNLA 369 ;V or DSKA 502 ;N did not block the cleavages but yielded the 65 and 58 kD cleavage fragments ( Figure 5A ). This suggested that the DNLD 369 ;V and DSKD 502 ;N sites are not used preferentially by caspase-3. The mutant containing DEVPA 30 ;G yielded a fragment that migrated slightly slower than the 65 kD fragment, with an approximately molecular weight of 68 kD, consistent with cleavage at the available DAQD 486 ;G site ( Figure 5A ). The mutant containing DAQA 486 ;G yielded a predominant fragment that migrated slightly faster than the wild-type, with an approximately molecular weight of 72 kD, consistent with cleavage at the available DEVPD 30 ;G site ( Figure 5A ). The mutant containing WEIA 85 ;N blocked the appearance of the 58 kD fragment but had no effect on the appearance of the 65 kD fragment, consistent with simultaneous cleavage at the available DEVPD 30 ;G and DAQD 486 ;G sites ( Figure  5A ). A double mutant, containing Asp?Ala substitutions at both positions Asp 30 and Asp 486 completely blocked the generation of the 65 and 58 kD fragments ( Figure 5A ). This confirmed that the 65 kD fragment is generated by simultaneous cleavage at the DEVPD 30 ;G and DAQD 486 ;G sites and serves as a precursor of the 58 kD fragment. These results were reproduced with caspase-7 and using the pcDNAledgf/p75 plasmid (see Materials and Methods) as template for in vitro TNT (data not shown).
To further verify these results, deletion mutants of LEDGF/p75 corresponding to cleavage fragments generated by caspases were amplified by PCR and inserted into a pcDNA3.1+ vector. These mutants were translated in vitro and incubated with recombinant caspase-3. These mutants were designated LEDGF/p75DN, which lacked Apoptotic cleavage of LEDGF/p75 X Wu et al residues 1 ± 30 and corresponded to the fragment generated by cleavage at the DEVPD 30 ;G site; LEDGF/p75DC, which lacked residues 487 ± 530 and corresponded to the fragment generated by cleavage at the DAQD 486 ;G site; and LEDGF/p75DNC, a double mutant lacking residues 1 ± 30 and 487 ± 530 that corresponded to the fragment generated by simultaneous cleavage at the DEVPD 30 ;G and DAQD 486 ;G sites. Figure 5B shows that the migration of the LEDGF/p75 deletion mutants in the presence of caspase-3 is consistent with cleavage at the sites identified in the experiments described in Figure 5A . LEDGF/p75DN migrated near the position of the wild-type LEDGF/p75, which is consistent with the expected migration of a fragment produced by cleavage at the DEVPD 30 ;G site but not at the DAQD 486 ;G site. Incubation of this fragment with caspase-3 produced the 65 and 58 kD fragments generated by cleavage of wild-type LEDGF/p75. LEDGF/ p75DC migrated at approximately 68 kD, consistent with the expected migration of a fragment produced by cleavage at the DAQD 486 ;G site but not at the DEVPD 30 ;G site. As expected, incubation of this fragment with caspase-3 also produced the 65 and 58 kD fragments. LEDGF/p75DNC migrated at 65 kD, corresponding to the fragment generated by cleavage at both DEVPD 30 ;G and DAQD 486 ;G sites. Incubation of this fragment with caspase-3 did not affect its migration but generated the 58 kD fragment corresponding to further cleavage at the WEID 85 N site. Figure 5C shows a schematic diagram of the LEDGF/p75 fragments that could be generated by caspase cleavage during apoptosis. It should be emphasized, however, that of these putative products only the 65 and 58 kD fragments were observed in apoptotic cells ( Figure 1 ) and during in vitro cleavage of the full-length protein (Figures 3 and 5A,B). Taken together, these results strongly suggest that the 65 kD apoptotic fragment of LEDGF/p75 is generated by simultaneous caspase cleavage at the DEVPD 30 ;G and DAQD 486 ;G sites. This fragment is subsequently cleaved at the WEID 85 ;N site to yield the 58 kD fragment.
Analysis of LEDGF/p75 sequences containing caspase cleavage sites
To determine if the identified caspase cleavage sites are conserved in LEDGF/p75 proteins from different species, we compared the LEDGF/p75 sequence with complete and unfinished genomes of mammalian species at www.tigr.org. Figure 6A shows that the DEVPD 30 ;G and WEID 85 ;N sites are conserved in LEDGF/p75 proteins from human, mouse, and rat. However, the DAQD 486 ;G site is conserved in bovine, but not in mouse LEDGF/p75 (the rat COOH-terminal sequence was not available). This suggests that DAQD 486 ;G may not be critical for the apoptotic cleavage of LEDGF/p75 in murine cells.
Effector caspases often cleave at sites adjacent to or within functionally important domains, activating or inactivating their target substrates. 36 ± 38 Although very little is known about functional domains within the LEDGF/p75 sequence, we investigated whether the DEVPD 30 ;G, WEID 85 ;N, and DAQD 486 ;G sites are located within regions or domains that could be associated with the reported survival and growth factor activities of this protein.
12,14 ± 22 Analysis of the LEDGF/p75 amino acid sequence against the ProDom database yielded a clearly defined domain (residues 6 ± 96) that corresponded to the highly conserved HATH region, previously identified in this protein and some members of the hepatoma-derived growth factor (HDGF) family. 12, 41 This region is also called the PWWP domain because of the presence of a highly conserved proline-tryptophan-tryptophan-proline motif. 41 A PSI-BLAST search against residues 1 ± 127 yielded 114 mammalian proteins with a HATH/PWWP domain. Proteins containing this domain included, in addition to members of the HDGF family, DNA mismatch repair proteins, DNA- Figure 6B ). In the LEDGF/p75 sequence, the DEVPD 30 ;G and WEID 85 ;N cleavage sites are located within the HATH/PWWP domain, with DEVPD 30 ;G immediately following the conserved PWWP motif (Figure 6 ). These cleavage sites are not conserved in other HATH/PWWP-containing proteins (except in p52, an alternative splicing product of LEDGFp75.) 11, 42 . However, other potential caspase cleavage sequences may exist in this domain. For example, mouse HRP2 (HDGF-related protein 2) and rat HDGF3 (equivalent to HRP2) have a DIAD sequence after the PWWP motif ( Figure 6B) . A PSI-BLAST search against the LEDGF/p75 COOHterminus (residues 346 ± 530) revealed moderate sequence conservation upstream the DAQD 486 ;G site in several members of the HDGF family, including human and mouse HRP2 and rat HRP3 (data not shown). The DAQD 486 ;G site was not conserved in any of these proteins. To study whether the apoptotic cleavage of LEDGF/p75 affects its pro-survival function, we generated stably transfected HepG2 cell lines expressing either LEDGF/p75 or its deletion mutants corresponding to caspase-generated fragments. HepG2 cells were chosen for these studies because they expressed relatively lower levels of endogenous LEDGF/p75 than other cell lines examined by immunoblotting (data not shown), and could be used to test the ability of this protein to confer protection against serum starvationinduced cell death. The expression of LEDGF/p75 and its deletion mutants LEDGF/p75DNC and LEDGF/p75DC (see above) in stably transfected HepG2 cells was confirmed by immunoblotting ( Figure 7A ). Cells stably transfected with pcDNA3.1+ vector alone had similar expression levels of LEDGF/p75 as untransfected HepG2 cells, while the protein was overexpressed in cells transfected with plasmid encoding the wild-type protein ( Figure 7A ). As expected, HepG2 cells stably expressing the LEDGF/p75DC and LEDGF/p75DNC mutants showed immunoreactive fragments of approximately 68 and 65 kD, respectively, in immunoblots ( Figure 7A ). The 65 kD fragment expressed in HepG2-LEDGF/p75DNC migrated at the same position as the larger fragment generated during STS-induced HepG2 apoptosis ( Figure 7A ). The expression level of LEDGF/ p75DNC was relatively low and its visualization in immunoblots required loading more cellular protein in the gels. Only a few clones expressing LEDGF/p75DNC were obtained, all of which expressed low levels of the mutant protein. This suggested that this mutant might be toxic to cells when expressed at high levels and that only cells expressing low levels were able to survive. Several attempts to generate HepG2 cells stably expressing LEDGF/p75DN were unsuccessful, suggesting that expression of this deletion mutant may be lethal.
The ability of LEDGF/p75 and its deletion mutants to protect HepG2 cells against serum starvation-induced death was examined. Figure 7C ± F shows that while cells transfected with vector alone underwent serum starvationinduced death ( Figure 7C ), cells transfected with LEDGF/ p75WT ( Figure 7D ) showed a normal morphology, comparable to that of untransfected HepG2 cells grown in the presence of 10% FBS ( Figure 7B) . Expression of the deletion mutants LEDGF/p75DC ( Figure 7E ) and LEDGF/p75DNC ( Figure 7F ) could not suppress serum starvation-induced cell death. To confirm these results, we examined the survival of the different stably transfected cell lines under serum-free conditions. Overexpression of wild-type LEDGF/p75 significantly protected against cell death, as compared with the survival of the HepG2-Vec clone ( Figure 8A ; P50.001). However, the individual expression of the LEDGF/p75DC and LEDGF/p75DNC mutants had no protective function against serum starvation-induced cell death ( Figure 8A ). While there was no significant difference between the survival of HepG2-Vec and HepG2-LEDGF/p75DC clones, expression of the LEDGF/p75DNC mutant significantly enhanced cell death, when compared with the survival of HepG2-Vec ( Figure  8A ; P50.001).
To test whether expression of the deletion mutants affected cell proliferation, the stably transfected cell lines were grown in the presence of 10% FBS for 24 and 48 h, followed by measurement of relative cell number. After 48 h, cell proliferation was significantly higher in HepG2 clones overexpressing LEDGF/p75WT, as compared with the proliferation of HepG2-Vec ( Figure 8B ; P50.05). Cells expressing LEDGF/p75DNC showed significantly lower cell proliferation when compared with HepG2-Vec ( Figure 8B ; P50.005). There was no significant difference between the relative cell number of HepG2-Vec and HepG2-LEDGF/ p75DC clones.
All these results were confirmed using at least two different stably transfected clones for each construct. The relevant finding in these experiments is that while overexpression of LEDGF/p75 protects against serum starvation-induced cell death, removal of sequences near its NH 2 -and COOH-terminal regions by caspases during apoptosis appeared to abrogate its pro-survival and growth factor functions. Elucidating the mechanisms that maintain the delicate balance between cell death and survival is essential for understanding the pathophysiology of a wide variety of human diseases. These mechanisms include the inactivation of prosurvival proteins, or their conversion into death effectors, during apoptosis by caspases cleaving at or near functionally important domains. 43 ± 46 The atopy-associated autoantigen LEDGF/p75 is a novel survival protein whose cleavage during apoptosis, along with other substrates, may ensure that the cellular pro-survival machinery does not antagonize the cell death process.
Here we present the first evidence that LEDGF/p75 is cleaved by caspases-3 and -7 during apoptosis and that this cleavage abrogates its pro-survival function. Our data indicates that abrogation of LEDGF/p75 pro-survival activity during apoptosis is dependent on the caspase-mediated removal of amino acid sequences near the NH 2 -and COOH-terminal regions by simultaneous cleavage at the DEVPD 30 ;G and DAQD 486 ;G sites. Interestingly, the DEVPD 30 ;G site was found to be located within the HATH/PWWP domain. While the function of this domain is still undefined, it was speculated that it could be involved in protein ± protein interactions influencing chromatin remodeling and thereby facilitating fine-tuning of transcription processes. 41 Our sequence homology search using PSI-BLAST indicated that the HATH/PWWP domain is present in at least 114 other eukaryotic proteins and that consensus caspase cleavage sites are not frequently present in this domain. This indicated that LEDGF/p75 may belong to a subset of cellular proteins whose HATH/PWWP domain is specifically targeted for cleavage during apoptosis.
Our results showed that cells stably expressing a deletion mutant corresponding to the 65 kD apoptotic fragment of LEDGF/p75 (called LEDGF/p75DNC) exhibited lower survival and proliferation than cells transfected with vector alone or expressing a fragment corresponding to single cleavage at the DAQD 486 ;G site (LEDGF/p75DC). These negative effects on cell growth and survival occurred in spite of the expression of low amounts of LEDGF/ p75DNC and the presence of endogenous LEDGF/p75 in the HepG2 cells. This suggested that preserving the integrity of the HATH/PWWP domain might be important for the pro-survival function of LEDGF/p75 and that its 65 kD apoptotic cleavage fragment may act as a dominant negative polypeptide that enhances cell death. Experiments are currently being conducted in our laboratory to confirm this dominant negative effect in various cell types.
The dominant negative effect of LEDGF/p75DNC on HepG2 cell survival suggests that the 65 kD cleavage fragment of LEDGF/p75 may acquire a novel pro-apoptotic function during cell death. This would be consistent with previous reports indicating that caspase cleavage of certain survival proteins, such as Bcl-2, Bcl-x L , and Akt/PkB, converts them into cell death effector proteins. 44 ± 46 Various scenarios could be envisioned to explain the pro-apoptotic activity of LEDGF/p75DNC. For instance, LEDGF/p75DNC may compete with its full-length anti-apoptotic counterpart for DNA binding, or form aberrant complexes with this and other proteins, resulting in blockade of transcription coactivation functions that might be essential for cell survival. There is evidence that the expression of full-length LEDGF/ p75 increases in cells subjected to environmental stresses, including thermal and oxidative stress, and that the protein confers protection against these stresses by upregulating the expression of stress-related, anti-apoptotic proteins such as heat shock protein 27 (HSP27), aB-crystallin, and AOP2. 12,14 ± 22 This upregulation is presumed to be mediated by binding of LEDGF/p75 to heat shock element (HSE) and stress-related regulatory elements (STRE) located in the promoters of stress-related genes. 15 While the ability of LEDGF/p75DNC to bind to promoter regions of stress related genes remains to be determined, sequence analysis using the BLOCKS program showed that there is a consensus AT-hook DNA binding motif (PRGRP; residues 194 ± 198) that is retained in this cleavage fragment. The presence of this motif facilitates the binding of transcription co-activators, such as high mobility group (HMG) proteins, to the minor groove of short stretches of AT-rich DNA sequences and is involved in the transcription regulation of genes containing, or in close proximity to, these sequences. 47 Thus, retention of the AT-hook motif predicts that LEDGF/p75DNC may still bind to DNA sequences, which would be consistent with the colocalization of the protein with fragmented chromatin in apoptotic keratinocytes. It is not clear, however, whether binding of this cleavage fragment to DNA may still promote the expression of pro-survival genes. It can not be ruled out that LEDGF/ p75DNC may acquire new transcription coactivator functions that promote the expression of pro-apoptotic genes. Alternatively, this cleavage fragment may have a cell deathinducing effect that is independent of its binding to DNA and transcription co-activator functions. This effect might be mediated by direct interaction with key elements of the apoptotic machinery, such as caspases, mitochondria, or inhibitors of apoptosis proteins (IAPs), via mechanisms yet to be defined.
The reduced pro-survival activity associated with expression of the DC fragment also implicated the COOHterminus of LEDGF/p75 in this function. Sequence homology analysis of the COOH-terminus of LEDGF/p75 using PSI-BLAST only retrieved a few HDGF-related proteins (HRPs) and indicated that the region corresponding to residues 338 ± 420 has several clusters of amino acids that are conserved among these proteins and might be part of a functional domain (data not shown). However, the lack of information on structure-function relationships within HRPs makes it difficult to ascertain a specific function to this region. It is possible that LEDGF/p75 and the HRPs may overlap in some functional activities because they share both a HATH/PWWP domain and moderate homology in the COOH-terminus.
Implications of LEDGF/p75 apoptotic cleavage for atopy-associated autoimmunity Autoimmunity to intracellular proteins has been recently identified as an important factor in the pathogenesis of atopic disorders, in particular AD.
4 ± 10 LEDGF/p75 has been identified as a prominent autoantigen (called DFS70) associated with atopy since 30% of patients with AD and 16% of patients with asthma were found to produce IgG and IgE autoantibodies that reacted with this protein in immunoblots. 4, 5 The factors leading to autoimmunity to intracellular proteins in AD are not clear, although various scenarios could be invoked to explain this phenomenon. For instance, immune responses directed to environmental allergens may spread to intracellular autoantigens that share structural similarities with these allergens, thus triggering an autoantibody response that is subsequently maintained by the human autoantigens. This molecular mimicry scenario is supported by structural similarities between some environmental allergens and intracellular autoantigens targeted in AD. 6 A more likely scenario is that tissue damage and aberrant cell death triggered by environmental allergens or intrinsic factors in the target organs of atopy (skin, eyes, respiratory tract, and gastrointestinal tract) could contribute to the release and exposure to the immune system of intracellular antigens. 6, 23 Apoptotic cells are considered reservoirs of potentially immunostimulatory forms of intracellular antigens. 31 ± 34 Massive apoptosis or defective clearance of apoptotic cells may lead to the accumulation of cells in late apoptotic stages or secondary necrosis, leading to the release of potentially harmful intracellular contents, such as proteases and pro-inflammatory signals, that could damage the surrounding tissue and provoke an inflammatory response. 28,33,34,48 ± 52 Under a pro-inflammatory environment, modified forms of intracellular antigens (e.g. produced by proteolysis) could be processed and presented by mature dendritic cells (DC) to circulating autoreactive T cells, thus triggering autoantibody responses.
Aberrant cell death, LEDGF/p75 inactivation by caspases, and autoimmunity to this protein could be interrelated events that might play an important role in the pathogenesis of AD. For instance, massive keratinocyte apoptosis may be induced in AD patients by proinflammatory lymphocytes activated by environmental allergens or other factors. This would be consistent with reports that dysregulated keratinocyte apoptosis induced by activated skin-infiltrating T-cells is a key pathogenic event in the skin lesions associated with AD. 23 ± 25 If not cleared swiftly by phagocytic cells, a number of apoptotic keratinocytes would undergo secondary necrosis, further enhancing the pro-inflammatory environment. 28,33,34,48 ± 50 In this environment, mature DC may process and present LEDGF/p75, its apoptotic fragments, and other modified proteins to autoreactive lymphocytes that have escaped deletion, leading to autoimmunity to these proteins. Keratinocyte apoptosis may also be amplified by the 65 kD apoptotic cleavage fragment of LEDGF/p75, which could function as a dominant negative protein that, if released from dying cells into the extracellular environment, might inhibit the survival and proliferation of neighboring cells. In an alternative scenario, anti-LEDGF/p75 autoantibodies may enhance loss of keratinocyte survival by binding to secreted intact LEDGF/p75, thus preventing its uptake by viable keratinocytes. There is evidence that LEDGF/p75 acts as a growth factor that can be secreted by cultured COS7 cells and stimulate the proliferation of neighboring cells that uptake the protein. 12 Addition of recombinant LEDGF/p75 to the medium of cultured lens cells has been shown to protect against stress-induced cell death. 16, 18 Moreover, deprivation of cultured lens epithelium cells (LEC) of LEDGF/p75 with anti-LEDGF/p75 antibodies was demonstrated to induce LEC death. 53 Similar mechanisms could also underlie other conditions associated with autoimmunity to LEDGF/p75, such as asthma, age-related cataract, interstitial cystitis, and VKH.
In conclusion, we provide evidence that LEDGF/p75, a nuclear autoantigen associated with certain atopic disorders and other chronic inflammatory conditions, is cleaved by effector caspases during apoptosis in a manner that abrogates its pro-survival function. We propose that the Cell Death and Differentiation Apoptotic cleavage of LEDGF/p75 X Wu et al apoptotic cleavage of LEDGF/p75 may contribute to the pathogenesis of these disorders by altering its pro-survival functions and enhancing its immunogenicity.
Materials and Methods
Cell culture and induction of apoptosis 
Electrophoresis and immunoblotting of cell lysates
Total cell lysates were prepared as described previously. 28 Protein concentrations in lysates were determined by the Protein DC Assay Kit (Bio-Rad) to ensure equal loading of proteins per lane in SDS polyacrylamide gels (Ready Gels, Bio-Rad). Electrophoresis and immunoblotting procedures were performed as described previously. 28 Immuno¯uorescence microscopy NHEK grown on coverslips were washed with phosphate buffered saline (PBS), fixed and permeabilized in methanol/acetone (3 : 1 v/v), and stained with a highly specific human anti-LEDGF/p75 serum. 4 FITC-conjugated goat anti-human IgG antibody (Caltag Laboratories) was used as secondary detecting reagent. Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI; Sigma) for DNA visualization. Labeled cells were examined under a fluorescence microscope.
Site directed mutagenesis
Site-directed mutagenesis of potential caspase cleavage sites within LEDGF/p75 was done by multiple rounds of polymerase chain reaction (PCR) using a pET28a-dfs70 plasmid containing the full-length LEDGF/p75 cDNA (residues 1 ± 530) under the control of a T7 promoter, 4 following the instructions for the QuikChange 2 sitedirected mutagenesis kit (Stratagene). LEDGF/p75 mutants were constructed to substitute aspartic acid residues in putative caspase cleavage sites by alanine residues. The point mutations generated were Asp 30 forward (5'-GATCTGATGCTCAAGCTGGTAATCAGCCAC-3'); DAQD 486 backward (5'-GTGGCTGATTACCAGCTTGAGCATCA-GATC-3'); DSKD 502 forward (5'-GAAGACAGCAAAGCCAACCAT-GAAGCCAG-3' ); DSKD 5 0 2 backward (5' -CTGGCTTCAT-GGTTGGCTTTGCTGTCTTC-3').
Site directed mutagenesis was also used to generate deletion mutants corresponding to caspase-generated fragments of LEDGF/ p75. For these experiments, the LEDGF/p75 cDNA cloned into in the pET28a-dfs70 plasmid was subcloned into a pcDNA3.1+ vector (Invitrogen) to generate a plasmid designated pcDNA-ledgf/p75. This plasmid was then used to create LEDGF/p75 mutants corresponding to the cleavage fragments. The constructs were made by sitedirected mutagenesis and PCR to generate plasmids designated pcDNA-ledgf/p75DN (lacking residues 1 ± 30), pcDNA-ledgf/p75DC (lacking residues 487 ± 530) and pcDNA-ledgf/p75DNC (lacking residues 1 ± 30 and 487 ± 530). For the construction of pcDNAledgf/p75DN, nucleotides coding for the NH 2 -terminus of LEDGF/p75 were deleted by site-directed mutagenesis (forward primer: 5'-GGAATTCGTTAACGCCACCATGGGAGC-3', backward primer: 5'-GCTCCCATGGTGGCGTTAACGAATTCC-3'). A stop codon TAA was inserted by site-directed mutagenesis into pcDNA-ledgf/p75 to generate pcDNA-ledgf/p75DC (forward primer, 5'-GGAGGATCTG-ATGCTCAAGATTAATCAGCCACAAC-3', backward primer, 5'-GTTGTGGCTGATTAATCTTGAGCATCAGATCCTCC-3'). The later set of primers was used to generate pcDNA-ledgf/p75DNC by inserting the stop codon into the pcDNA-ledgf/p75DN plasmid. Details on the construction of these mutants are available upon request.
In vitro cleavage of LEDGF/p75 by recombinant caspases LEDGF/p75 was synthesized in vitro using the TNT Coupled Reticulocyte Lysate System (Promega) and labeled with biotinylated lysine using the Transcend 2 Non-Radioactive Translation Detection System (Promega), following the manufacturer's instruction. DNA templates used for in vitro transcription/translation (TNT) were pET28a-dfs70 and pcDNA-ledgf/p75. In the pET28a-dfs70 plasmid, the LEDGF/p75 sequence was fused to T7 protein and 6x-histidine tags. Five ml aliquots of the in vitro translated LEDGF/p75 were incubated with different concentrations of recombinant caspases-3, -6, -7, -8 and -9 (Pharmingen) in cleavage buffer (20 mM PIPES, pH 7.2, 100 mM NaCl, 1 mM EDTA, 0.1% CHAPS, 10% sucrose, 100 mM DTT) at 378C for 90 ± 120 min. An equal volume of SDS ± PAGE sample buffer was added after incubation followed by heating at 958C for 5 min. Protein samples were subjected to SDS ± PAGE and transferred to nitrocellulose membranes. In vitro translated proteins, labeled with biotinylated lysine, were detected by chemiluminescence (NEN Life Science).
Transfection experiments
For expression of LEDGF/p75 and its mutants in mammalian cells, we transfected human HepG2 cells with plasmids pcDNA-ledgf/p75, pcDNA-ledgf/p75DN, pcDNA-ledgf/p75DC and pcDNA-ledgf/p75DNC. Expression of LEDGF/p75 and its mutants was under the control of CMV promoter. HepG2 cells (1610 6 cells per 60 mm dish) were transfected with 1 mg of the above constructs using Effectene (Qiagen Inc.). Transfected HepG2 cells were grown in Dulbecco s Modified Eagle Medium (DMEM) containing 600 mg/ml of G418 (Fisher Biotech) for up to 30 days to generate stably transfected cell clones. HepG2 clones were obtained stably expressing full-length/wild-type LEDGF/ p75 (HepG2-LEDGF/p75WT) and two deletion mutants (HepG2-LEDGF/p75DNC and HepG2-LEDGF/p75DC). Cells transfected with pcDNA3.1+ vector alone, used as control, were designated HepG2-Vec.
